Research Reports

Key takeaways

Stockholders approved increase of 1,500,000 shares under Second Amended and Restated 2017 Equity Incentive Plan.

Gary J. Bridger, Ph.D., Françoise De Craecker, and Michael S. Wyzga elected as directors until 2029 Annual Meeting.

Proposal 3 passed with 58.7M FOR vs. 17.7M AGAINST, despite broker non-votes.

Ratified PricewaterhouseCoopers LLP as independent auditors for fiscal year ending December 31, 2026.

Non-binding say-on-pay for named executive officers approved with 70.9M FOR vs. 5.4M AGAINST.

Full analysis

The approval of the Second Amended and Restated 2017 Equity Incentive Plan adds 1,500,000 shares to the pool available for equity awards, enhancing the company's ability to attract, retain, and motivate employees, officers, and directors through performance-based incentives aligned with stockholder interests. All three director nominees received majority support and will serve until the 2029 Annual Meeting. Auditor ratification passed overwhelmingly with minimal opposition. The say-on-pay proposal received strong backing, indicating stockholder approval of disclosed executive compensation practices.

XFOR · X4 Pharmaceuticals, Inc.

Summary

Key takeaways

Full analysis